Add like
Add dislike
Add to saved papers

MicroRNA-497-5p Suppresses Tumor Cell Growth of Osteosarcoma by Targeting ADP Ribosylation Factor-Like Protein 2.

BACKGROUND: Osteosarcoma (OS) is a frequent primary bone malignancy. MicroRNA-497-5p (miR-497-5p) has been recently reported to be downregulated in angiosarcoma, but its potential role in OS remains unclear.

METHODS: Quantitative real-time polymerase chain reaction was used to determine miR-497-5p expression in OS tissues and cell lines. The effect of miR-497-5p on cell growth, cell cycle progression and apoptosis were measured using CCK-8 and flow cytometry assays, respectively. The effect of miR-497-5p on ADP-ribosylation factor-like protein 2 (ARL2) was determined by luciferase reporter assay and western blot.

RESULTS: We found miR-497-5p was significantly downregulated in OS tissues and cells. Overexpression of miR-497-5p in OS cells inhibited tumor cell proliferation and induced a significant G0/G1 cell cycle arrest and apoptosis in vitro. Additionally, we found ARL2 was a new target of miR-497-5p. Moreover, ARL2 and P-p53 protein levels were significantly downregulated by treatment with miR-497-5p mimics in OS cells.

CONCLUSIONS: Taken together, our findings revealed miR-497-5p may be a tumor suppressor in OS and serve as a promising therapeutic target for OS.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app